IDH1 and myelodysplastic syndrome: Recurrent TET2, DNMT3A, IDH1/2 mutations have been observed in patients with myeloproliferative neoplasms and other hematological malignancies, such as acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or myelodysplastic syndromes (MDS) [38,39].